A Phase 2/3 interventional study of polydioxanone (PDO) mono threads and Mono Threads with Plasma Gel in Acne, sponsored by Tanta University. Enrolling by invitation at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by Tanta University · Phase 2/3, Interventional, and Treatment
This study aims to evaluate and compare the efficacy and safety of mono threads alone versus mono threads combined with plasma gel for the treatment of atrophic post-acne scars. Using a prospective, randomized, split-face design, participants receive mono threads on both sides of the face, followed one month later by plasma gel injection on one side and saline injection on the other. Treatment outcomes are assessed using standardized clinical photographs, the Goodman Quantitative Global Scarring Grading System, the ECCA scar grading scale, qualitative scar severity grading, and patient-reported quality of life and satisfaction measures. The study also evaluates treatment-related adverse effects, including erythema, edema, pain, and ecchymosis. The findings aim to determine whether adding plasma gel to mono threads provides greater clinical improvement and better patient-reported outcomes than mono threads with saline.
790 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.
This study's planned enrollment of 20 is below the median of 70 across 672 interventional studies indexed under Acne Vulgaris.
Browse Acne Vulgaris studies →Tanta University is the lead sponsor of 1,010 studies on the registry; 321 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive polydioxanone (PDO) mono threads inserted into the mid dermis on the assigned side of the face using a cross-hatch technique. Six to ten threads are inserted according to acne scar severity. One month after thread insertion, plasma gel is injected into the mid and deep dermis and gently massaged into the skin. Clinical outcomes are assessed using standardized photographs, acne scar grading scales, and other study outcome measures.
Drug: polydioxanone (PDO) mono threads
Participants receive polydioxanone (PDO) mono threads on the assigned side of the face, followed by plasma gel injection one month later. Six to ten threads are inserted into the mid dermis using a cross-hatch technique, according to acne scar severity. Plasma gel is subsequently injected into the mid and deep dermis and gently massaged into the skin.
Drug: Mono Threads with Plasma Gel
Participants receive polydioxanone (PDO) mono threads on the assigned side of the face, followed by saline injection one month later. Six to ten threads are inserted into the mid dermis using a cross-hatch technique, according to acne scar severity.
Drug page: Human plasma
Participants receive polydioxanone (PDO) mono threads on the assigned side of the face, followed by plasma gel injection one month later. Six to ten threads are inserted into the mid dermis using a cross-hatch technique, according to acne scar severity. Plasma gel is subsequently injected into the mid and deep dermis and gently massaged into the skin.
Also known as: Plasma
Number of participants with improvement
Treatment outcome is assessed using standardized clinical photographs
Time frame: 6 months
Goodman Quantitative Global Scarring Score
Change in Goodman Quantitative Global Scarring Score from baseline.
Time frame: Baseline to 3 months after the final treatment session.
ECCA Scar Score
Change in the Echelle d'Évaluation Clinique des Cicatrices d'Acné (ECCA) score from baseline.
Time frame: Baseline to 3 months after the final treatment session.
Qualitative Scarring Grade
Distribution of participants across mild, moderate, and severe acne scar grades.
Time frame: Baseline and 3 months after the final treatment session.
Plan to share: Yes — De-identified individual participant data underlying the results reported in the publication, including relevant clinical characteristics, acne scar severity scores, clinical improvement assessments, quality-of-life assessments, patient satisfaction, and safety outcomes, will be available upon reasonable request, subject to applicable ethical and privacy requirements.
Supporting information: Study protocol
Time frame: following publication
Access criteria: Requests should be submitted to the corresponding author with a brief description of the research objectives and intended use of the data. Access will be considered on a reasonable request basis, subject to ethical approval where applicable, protection of participant confidentiality, and any necessary data-sharing agreement.
Started Nov 2025 (actual). Primary completion is estimated for Nov 2026, 11 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.